Antifungal Activity of Brazilian Propolis Microparticles against Yeasts Isolated from Vulvovaginal Candidiasis

Table 1

Interpretation of the results of MIC for antifungal drugs against vaginal yeasts of C. albicans (n = 58) and non-C. albicans (n = 31).

	Candida albicans						Non-Candida albicans
Antifungals	S^a		DDS^b		R^c		S		DDS		R
	n	%	n	%	n	%	n	%	n	%	n	%
FLU	55	94.8	3	5.2	—	—	26	83.9	5	16.1	—	—
ITRA	48	82.8	4	6.9	6	10.3	18	58.1	4	12.9	9	29.0
KETO	20	34.5	23	9.7	15	25.8	9	29.0	7	22.6	15	48.4
MICO	42	72.4	14	24.1	2	3.5	6	19.4	20	64.5	5	16.1
VORI	57	98.3	1	1.7	—	—	30	96.8	1	3.2	—	—
AMB	57	98.3	—	—	1	1.7	31	100.0	—	—	—	—

DDS, dose-dependent susceptibility; R, resistant.
^aS: Isolates with MIC ≤ 8  μg mL^–1 for FLU, ≤0.125 μg mL^-1 for ITRA, KETO, and MICO, and ≤1 μg mL^–1 for AMB and VORI, ^bDDS: Endpoints for antifungal agents: isolates with MIC between 16 and 32 μg mL^–1 for FLU, 0.25–0.5 μg mL^–1 for ITRA, KETO, and MICO, and 2 μg mL^–1 for VORI, ^cR: Isolates with MIC ≥ 64 μg mL^–1 for FLU, ≥1 μg mL^–1 for ITRA, KETO, and MICO, ≥ 4 μg mL^–1 for VORI and ≥2 μg mL^–1 for AMB.